News headlines about Alder Biopharmaceuticals (NASDAQ:ALDR) have trended positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alder Biopharmaceuticals earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.9104487792007 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s rankings:
- Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) – In Play Stock Characteristics – Nasdaq Journal (nasdaqjournal.com)
- Today’s Hot Mover – Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR) – The Investor Guide (wallstreetnews24.com)
- Alder Biopharmaceuticals, Inc. (ALDR) has analyst mean rating score of 2.00 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Alder Biopharmaceuticals Inc (ALDR) Expected to Earn FY2020 Earnings of ($3.32) Per Share (americanbankingnews.com)
- Alder Biopharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark (investors.com)
Several equities research analysts have recently issued reports on ALDR shares. BidaskClub lowered shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Leerink Swann restated an “outperform” rating on shares of Alder Biopharmaceuticals in a research note on Sunday, March 4th. Zacks Investment Research upgraded shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Cowen set a $23.00 price target on shares of Alder Biopharmaceuticals and gave the stock a “buy” rating in a research note on Monday, February 26th. Finally, ValuEngine lowered shares of Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. Alder Biopharmaceuticals has an average rating of “Buy” and a consensus target price of $28.14.
Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.23. The firm had revenue of $0.94 million for the quarter. During the same period in the prior year, the business earned ($0.97) EPS. analysts expect that Alder Biopharmaceuticals will post -4.24 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Alder Biopharmaceuticals (NASDAQ:ALDR) Given News Sentiment Score of 0.28” was originally published by BBNS and is the sole property of of BBNS. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://baseballnewssource.com/2018/03/20/alder-biopharmaceuticals-aldr-given-daily-media-sentiment-score-of-0-28/2022036.html.
About Alder Biopharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.